Jade Biosciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 |
|---|---|---|---|---|
| Operating income | -$113.5M | -$74.6M | -$81.4M | -$53.2M |
| Operating expenses | $113.5M | $74.6M | $81.4M | $53.2M |
| Cash from operations | -$94.7M | -$71.2M | -$56.8M | -$39.1M |
| Capital expenditure | $196,000 | — | $142,000 | $195,000 |
| Free cash flow | -$94.9M | — | -$56.9M | -$39.3M |
| Impairments | — | — | $0 | $0 |
| Total assets | $349.8M | $72.8M | $127.4M | $135.3M |
| Total liabilities | $17.3M | $119.6M | $18.0M | $8.6M |
Shares outstanding 49.4M · Free float 92.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.